A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH
Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-75
SponsorJazz Pharmaceuticals
About this trial
The purpose of this study is to evaluate the efficacy and safety of expanded Xywav dosing regimens in adult participants with narcolepsy or idiopathic hypersomnia (IH).
Eligibility criteria
Qualifiers
Has a primary diagnosis of IH or narcolepsy Type 1 or Type 2 (NT1 or NT2)
If not currently treated with oxybate, has clinically significant symptoms of excessive daytime sleepiness (EDS) with an Epworth Sleepiness Scale (ESS) score > 11 at screening.
If currently treated with oxybate, must have documented improvement of EDS with oxybate treatment per the investigator's clinical judgement.
If currently treated with oxybate, has been taking the same stable dosing regimen at a total nightly dosage of 3 g to 9 g (inclusive) for at least 2 months at screening.
Disqualifiers
Shows evidence of a previous untreated or inadequately treated sleep disorder considered by the investigator to negatively impact the conduct of the study, including sleep-disordered breathing, parasomnias, circadian rhythm sleep disorders, or restless legs syndrome determined by a previous sleep-laboratory diagnosis or interview utilizing modules of the Diagnostic Interview for Sleep Patterns and Disorders.
Has succinic semi-aldehyde dehydrogenase deficiency by medical history.
Has uncontrolled hypothyroidism as determined by central clinical laboratory test results.
Has a current seizure disorder.
Trial design
Treatments tested in this trial
- Xywav
- Placebo
Treatment groups
108 Participants
are divided into 4 treatment groupsSponsors and collaborators
Jazz Pharmaceuticals
Lead sponsor
Jazz Pharmaceuticals Ireland Limited
Collaborator
Source ClinicalTrials.gov